

# Clinical trials of Eptifibatide

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
<b>Eptifibatide + tenecteplase vs primary intervention</b>			
<b>ADVANCE-MI , 2005</b> n=69/77 follow-up: 30 days	-	symptom duration <4h	
<b>Eptifibatide vs primary intervention</b>			
<b>INTAMI (Zeymer) , 2005</b> n=53/49 follow-up: 30-day	facilitated PCI with Eptifibatide; 180 g/kg intravenous double bolus, 20 g/kg per min infusion versus primary intervention	symptom duration <12h	

└ More details and results :

- myocardial revascularization for acute myocardial infarction in facilitated PCI at <http://www.trialresultscenter.org/go-Q90>

## References

### ADVANCE-MI, 2005:

Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. Am Heart J 2005;150:116-22 [[16084157](#)]

### INTAMI (Zeymer), 2005:

Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, Seidl K, Schrder R, Schneider S, Senges J Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 2005;26:1971-7 [[15857851](#)]

## 2 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
<b>bivalirudin + eptifibatide vs heparin + GP2b3a inhibitors</b>			
Kleiman , 2002 n=NA follow-up:	bivalirudin + eptifibatide versus heparin + eptifibatide	patients who underwent elective percutaneous coronary intervention	Parallel groups open
<b>Eptifibatide vs placebo</b>			
ESPRIT , 2000 n=NA	-	Nonurgent PCI	
IMPACT (4h) , 1995 n=NA	-	Elective PCI	
IMPACT-II (0.5g) , 1997 n=NA	-	Any PCI	
Harrington , 1995 n=NA	-	-	

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>
- anticoagulant for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q388>

## References

### Kleiman, 2002:

Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T, Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J 2002;143:585-93. [[11923794](#)]

### ESPRIT, 2000:

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-44 [[11145489](#)]

### IMPACT (4h), 1995:

Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 1995;91:2151-7 [[7697843](#)]

### IMPACT-II (0.5g), 1997:

Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422-8 [[9164315](#)]

### Harrington, 1995:

Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-7 [[7503000](#)]

Entry terms: bivalirudin, Hirulog-1 Hirulog Angiomax, tenecteplase, tenecteplase, Metalyse, Boehringer Ingelheim brand of tenecteplase, TNKase, Hoffmann-La Roche brand of tenecteplase, Genentech brand of tenecteplase, , eptifibatide, Integrilin, Integrelin